Albany Molecular Research Stock Rating Reaffirmed by Morgan Stanley (AMRI)
Albany Molecular Research (NASDAQ:AMRI)‘s stock had its “overweight” rating reaffirmed by stock analysts at Morgan Stanley in a report issued on Wednesday. They currently have a $21.00 target price on the stock, up from their previous target price of $19.00. Morgan Stanley’s price target would indicate a potential upside of 20.41% from the stock’s previous close.
The analysts wrote, “Following recent OsoBio acq. we update ests & raise PT to $21. With M&A strategy tracking ahead of expectations, we have increased confidence in bull case unfolding & highlight AMRI as a top pick in our coverage for 2H14.”
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet upgraded shares of Albany Molecular Research from a “hold” rating to a “buy” rating in a research note on Wednesday, June 4th. Finally, analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 15th. They now have a $17.80 price target on the stock.
In other Albany Molecular Research news, SVP Steven R. Hagen sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $16.93, for a total value of $42,325.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Albany Molecular Research (NASDAQ:AMRI) opened at 17.92 on Wednesday. Albany Molecular Research has a 1-year low of $9.71 and a 1-year high of $20.55. The stock’s 50-day moving average is $16.09 and its 200-day moving average is $14.07. The company has a market cap of $563.7 million and a price-to-earnings ratio of 57.56.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Tuesday, May 6th. The company reported $0.16 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. On average, analysts predict that Albany Molecular Research will post $0.82 earnings per share for the current fiscal year.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.